Novocure reports Q3 2026 results, raises 2026 guidance and announces Japan approval for Optune Pax
Novocure posted third‑quarter 2026 net revenue of $193.4 million, a 16% year‑over‑year increase, while recording a net loss of $10.4 million ($0.09 per share). Adjusted EBITDA reached $15.7 million. The company lifted its full‑year 2026 revenue outlook to $736 million‑$743 million and its adjusted EBITDA target to $24 million‑$34 million. In October, Japan’s health ministry approved Optune Pax for locally advanced pancreatic cancer, and Novocure announced a collaboration with Verastem Oncology on pancreatic‑cancer trials.
Why it matters
The company said the raised guidance reflects confidence in continued top‑line growth, but the quarter’s loss shows profitability is still a work‑in‑progress. The Japan approval of Optune Pax could add a new revenue stream, supporting future growth, as noted by the company.
Key facts
- 1Q3 2026 net revenue was $193.4 million, up 16% year‑over‑year. sec.gov
- 2Net loss for the quarter was $10.4 million, or $0.09 per share. sec.gov
- 3Adjusted EBITDA for the quarter was $15.7 million. sec.gov
- 4Full‑year 2026 net revenue guidance was raised to $736 million‑$743 million. sec.gov
- 5Adjusted EBITDA guidance for 2026 was set to $24 million‑$34 million. sec.gov
- 6Optune Pax received approval in Japan for locally advanced pancreatic cancer. sec.gov
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.